论文部分内容阅读
目的：探讨骨肿瘤复发前后在细胞的多药耐药性和凋亡方面的变化。方法：应用免疫组化和流式免疫学方法测定Ｐ１７０、ｂｃｌ－２蛋白在８例骨肿瘤复发前后的１６个标本中的表达，男６例，女２例。年龄平均３０６岁。良性肿瘤２例，恶性肿瘤６例。结果：２例良性肿瘤在复发前后Ｐ１７０、ｂｃｌ－２蛋白表达无明显差异。６例恶性肿瘤中，原发仅２例Ｐ１７０为阳性，复发后５例为阳性；复发后ｂｃｌ－２含量明显高于原发（Ｐ＜００５）。结论：恶性骨肿瘤复发后细胞的多药耐药性和增殖能力有增强的趋势。
Objective: To investigate the changes of multidrug resistance and apoptosis before and after bone tumor recurrence. Methods: Immunohistochemistry and flow immunoassay were used to measure the expression of P170 and bcl-2 protein in 16 specimens before and after recurrence of 8 cases of bone tumors. There were 6 males and 2 females. The average age is 30 to 6 years old. There were 2 benign tumors and 6 malignant tumors. Results: There were no significant differences in the expression of P170 and bcl-2 protein in two benign tumors before and after recurrence. In 6 cases of malignant tumors, only 2 cases of primary P170 were positive, and 5 cases of recurrence were positive. After recurrence, the bcl-2 content was significantly higher than that of the original (P<0. 05). CONCLUSION: The multidrug resistance and proliferation of cells after malignant bone tumor recurrence tend to increase.